In a potentially pivotal trial, PTC Therapeutics' experimental therapy for Huntington's disease (HD) met its primary endpoint, but questions about the data have raised doubts about the company's ...
Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics for a whopping $1 billion upfront. The deal – which has a potential total ...
Last time, our engineer covered the audio equipment stacks on either side of his laptop. But what do they connect to? What ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback